Concepedia

Author

Randall Severance

Radiant Research (United States)ORCID

Also Known As

Daniel Schlosser, Howard Schwartz, Randall Severance

11

Publications

817

Citations

8

H-Index

12

Concepts

All Affiliations

Radiant Research (United States)
RS

About

Randall Severance is an author at Radiant Research (United States) specializing in pharmacology, medicine, and cardiovascular pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

96

2

Pharmacology

2

2

96

3

Health Sciences

1

1

85

4

Hepatology

1

1

85

5

Metabolism

1

1

85

Randall Severance

×

6

Publications

523

Citations

6

H-Index

YearCitations

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Michel Farnier, Peter J.H. Jones, Randall Severance,

Atherosclerosis

2015

186

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Sam Jackson, Joseph R. Lentino, James Kopp,

Vaccine

2017

185

LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial

Rohit Loomba, Joel Neutel, Rizwana Mohseni,

Journal of Hepatology

2019

85

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

Remon Abu‐Elyazeed, William Jennings, Randall Severance,

Human Vaccines & Immunotherapeutics

2018

37

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)

Randall Severance, Howard Schwartz, Ron Dagan,

Human Vaccines & Immunotherapeutics

2021

19

Efficacy and Safety of Combining Alirocumab With Atorvastatin or Rosuvastatin versus Statin Intensification or Adding Ezetimibe in High Cardiovascular Risk Patients: ODYSSEY OPTIONS I and II

Harold Bays, Michel Farnier, Daniel Gaudet,

Kölner Universitäts PublikationsServer (Universität zu Köln)

2014

11

Page 1